Kornimate/medical-research-clean huggingface dataset:
effect of hippotherapy in children with down syndrome

Conditions: Down Syndrome

Summary: purpose: the aim of this study was to determine the effect of hippotherapy on balance, functional mobility, and functional independence in children with down syndrome (ds). methods: thirty-four children with ds were randomly assigned to the experimental (hippotherapy) and control groups after initial assessment. both groups received physiotherapy including balance exercises, and the experimental group also received hippotherapy. pediatric balance scale (pbs), timed up and go test (tug), and functional independence measure for children (weefim) were used before and after the intervention.

purpose: the aim of this study was to determine the effect of hippotherapy on balance, functional mobility, and functional independence in children with down syndrome (ds). methods: thirty-four children with ds were randomly assigned to the experimental (hippotherapy) and control groups after initial assessment. both groups received physiotherapy including balance exercises, and the experimental group also received hippotherapy. pediatric balance scale (pbs), timed up and go test (tug), and functional independence measure for children (weefim) were used before and after the intervention.

Eligibility criteria:
inclusion criteria: * diagnosed with down syndrome * being aged 4 to 14 years * being voluntary exclusion criteria: * having a history of previous hippotherapy intervention, * having a phobia related to horse riding, epileptic seizures, atlantoaxial instability, and * having any orthopedic, neurological, or cardiovascular disease that prevents physical activity.

Keywords: hippotherapy functional mobility balance down syndrome
mulligan mobilization with laser for shoulder adhesive capsulitis

Conditions: Shoulder Adhesive Capsulitis

Summary: adhesive capsulitis (frozen shoulder) is a condition of uncertain etiology characterized by pain and progressive loss of both active and passive shoulder motion. shoulder pain and stiffness are accompanied by disability. it is thought that the incidence is 3 to 5% in the general population. laser therapy is widely used for treating different musculoskeletal diseases, because of its ability to reduce pain and improve the physical function. also, mwm when used for shoulders with limited range of motion because of pain had shown improvement in range of motion and pressure pain threshold. previous studies have investigated the efficacy of combining different manual technique with lllt for treating pain in some body parts. however, up till now the combined effect of mwm with lllt for treatment of patients with shoulder adhesive capsulitis have not been investigated. so, the present randomized controlled study will be conducted to investigate the effect of adding mulligan mobilization with movement to low level laser therapy in treatment of patients with shoulder adhesive capsulitis.


Eligibility criteria:
inclusion criteria: * the participant selected for the study were patients (both male and female). * subjects diagnosed diagnosed by physicians with magnetic resonance imaging (mri). \& referred by an orthopedician with stage 2 adhesive capsulitis. * age group of 40-60 years of old. * painful condition of at least 3 months with 50% restriction in passive shoulder flexion, abduction and external rotation, in a sagittal plane compared with opposite side. * the severity of pain on visual analogue scale was higher than three out of ten, pain aggravated by movements. * patients were suffering from pain and limitation in the motion for more than 3 month. exclusion criteria: * patients with any shoulder injury or trauma, surgical release of capsule. * previous manipulation done under anaesthesia of the affected shoulder in the preceding 4 weeks. * other conditions involving the shoulder (eg. rheumatoid arthritis, osteoarthritis, damage of the glenohumeral cartilage, osteoporosis, or malignancies in the shoulder region). * pain or disorders of the cervical spine, elbow, wrist, or hand. * presence of medical conditions such as cardiac disease, infections, coagulation disorder. * patients having any intra articular injection, or physiotherapy treatment in the affected shoulder during the last three months. * patients with musculoskeletal disorder (any type of fracture), any history of surgery on that shoulder and patients with tendon calcification, patients with cervical rib, rotator cuff tear patients. * patients have insulin-dependent diabetes mellitus. * bilateral frozen shoulder * systemic inflammatory joint disease (such as rheumatoid arthritis or polymyalgia rheumatica).
high radiofrequency power for faster and safer pulmonary veins isolation - a pilot observational study.

Conditions: Cardiac Arrhythmia; Atrial Fibrillation; Atrial Tachycardia; Esophagus Injury

Summary: the power fast i pilot study is a unicentric, observational, non-randomized controlled clinical study. in the control group pulmonary veins isolation was performded in consecutive patients with irrigated radiofrequency cateters without contact force-sensing capabilities and using conventional low-power and long-duration radiofrequency parameters (20-30 w, 30-60 s) under continuous intracardiac-echo image and esophageal temperature monitoring. the study group consist of consecutive patients distributed in three succesive subgroups. in the study group radiofrequency ablation was performed using a point-by-point technique with contact-force catheters with different high-power and short-duration parameters: * subgroup 50w: power 50 w, application duration ≤ 30 s, target lesion index: lsi ≥ 5 or ablation index ≥ 350 (posterior wall) or ≥400 (anterior wall). * subgroup 60w: power 60 w, application duration 7-10 s, contact force ≥5 g. * subgroup 70w: power 70 w, application duration 9 s, contact force ≥5 g. the safety endpoint was evaluated with systematic esophageal endoscopy performed \<72 h after the index procedure. the efficacy endpoint was evaluated: * during the ablation procedure: acute procedural efficacy, firts-pass isolation of ipsilateral pulmonary veins, total radiofrequency and procedural time, acute reconnections and dormant conduction, * during the follow-up: any atrial tachycardias documented and longer than 30 s were considered recurrences.


Eligibility criteria:
inclusion criteria: * consecutive and unselected patients with a class i-iia indication for ablation of paroxysmal or persistent af. * informed consent. exclusion criteria: * previous surgical or catheter-based pvi. * stroke or acute coronary syndrome \<6 months before ablation. * terminal comorbidities. * frailty, or clinical instability. * absolute contraindication for oral anticoagulation.

Keywords: atrial fibrillation ablatión high-power radiofrequency esophageal lesion
anxiety sensitivity program for smoking cessation

Conditions: Smoking Cessation

Summary: the purpose of this study is to develop and test a smoking cessation intervention for persons who are specifically sensitive to anxiety and anxiety-related bodily sensations.


Eligibility criteria:
inclusion criteria: 1. aged between 18 and 65 years old 2. not pregnant 3. regular smoker averaging 10 or more cigarettes per day for at least one year 4. score of 25 or greater on 16-item anxiety sensitivity index 5. motivation to quit score of 7 or greater (using readiness to quit ladder) 6. not currently using pharmacotherapy for smoking cessation (e.g., zyban) 7. no use of other tobacco products (e.g., chewing tobacco, cigars) 8. no axis-i or axis-ii diagnoses other than mood or anxiety disorders (intake interview required) 9. no suicidal or homicidal ideation 10. no current psychotropic medication use 11. no evidence of substance abuse or dependence (other than nicotine dependence) 12. no history of significant medical conditions (cardiovascular, neurological, etc.) 13. ability to provide informed, written consent (no evidence of limited mental capacity) 14. sufficient command of the english language (able to carry on interview conversation) 15. plan to stay in burlington vt area for at least next 6 months exclusion criteria: 1. not between 18-65 years old 2. pregnant or currently trying to become pregnant 3. regular smoker for less than one year or smoke less than 10 cigarettes per day 4. asi below cutoff level of 25 5. motivation to quit score of 6 or less (using readiness to quit ladder) 6. current or recent use of any pharmacotherapy for smoking cessation (e.g., patch, zyban) 7. current use of other tobacco products (e.g., chewing tobacco, cigars) 8. axis-i disorders other than anxiety or mood disorders. 9. endorsement of suicidality or homicidal ideation. 10. any current psychotropic medication use (must have stopped at least 1 month prior). 11. any evidence of substance abuse or dependence (other than nicotine dependence) 12. any history of significant medical conditions (cardiovascular, neurological, etc.) 13. inability to provide informed, written consent (evidence of limited mental capacity) 14. insufficient command of the english language (unable to carry on conversation) 15. plan to permanently leave burlington area anytime during the next 6-12 months

Keywords: anxiety sensitivity
a study of bimagrumab (ly3985863) and tirzepatide (ly3298176), alone or in combination, in participants with obesity or overweight with type 2 diabetes

Conditions: Obesity; Overweight

Summary: the main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. participation in the study will last about 13 months.


Eligibility criteria:
inclusion criteria: * have type 2 diabetes * have a bmi of ≥27 kilograms per square meter (kg/m2) * have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss) exclusion criteria: * have a prior or planned surgical treatment for obesity, * have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma * have poorly controlled hypertension * have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * have a history of new york heart association (nyha) functional classification iii or iv congestive heart failure * have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes * have ongoing or a history of bradyarrhythmias other than sinus bradycardia * have renal impairment * have a history of symptomatic gallbladder disease within the past 2 years * have signs and symptoms of any liver disease * have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality * have a history of acute or chronic pancreatitis * currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening

Keywords: type 2 diabetes muscle lean fat
a study of escalating doses of polatuzumab vedotin in participants with relapsed or refractory b-cell non-hodgkins lymphoma and chronic lymphocytic leukemia and polatuzumab vedotin in combination with rituximab in participants with relapsed or refractory b-cell non-hodgkins lymphoma

Conditions: Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia

Summary: this is a phase i, multicenter, open-label, dose-escalation study of polatuzumab vedotin administered as a single agent by intravenous (iv) infusion to participants with relapsed or refractory hematologic malignancies. in phase ib, participants will receive polatuzumab vedotin in combination with rituximab.


Eligibility criteria:
inclusion criteria: * life expectancy of at least 12 weeks * history of one of the following histologically-documented hematologic malignancy for which no effective standard therapy exists: indolent non hodgkin's lymphoma (nhl), grade 3b follicular lymphoma (fl), diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), or chronic lymphocytic leukemia (cll) * all participants (nhl and b-cell chronic lymphocytic leukemia \[b-cll\]) must have at least one bi-dimensionally measurable lesion * for all men or women of childbearing potential (unless surgically sterile): use of adequate methods of contraception such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly exclusion criteria: * prior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks before cycle 1, day 1 * treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent within 2 weeks prior to cycle 1, day 1. adverse events from any previous treatments must be resolved or stabilized prior to cycle 1, day 1, except for neuropathy * completion of autologous stem cell transplant within 100 days prior to cycle 1, day 1 * prior allogeneic stem cell transplant
twin sublivac® grasses clinical efficacy study

Conditions: Rhinitis, Allergic, Seasonal; Conjunctivitis, Allergic

Summary: to show that treatment with sublivac® grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from ige mediated allergic complaints triggered by grass pollen.

indication under study: ige mediated allergic disorders triggered by grass pollen. number of centres: approximately 50. study period planned: q2-2006 until q3-2008 analysis after one exposed season (2007); based on the outcome the study will be stopped or continued for another season. subject selection criteria: seasonal rhinitis and/or rhinoconjunctivitis with or without mild asthma (fev1 \> 70%) related to grass pollen, age 12 years or older. dosage schedule: start with two drops daily of sublivac® and increase by two drops daily, until the maintenance dose of 10 drops sublivac® grassessublivac® grasses is reached. route of administration: sublingual application (drops are to be held underneath the tongue for 2-3 minutes and then will be swallowed). duration of treatment: 6 to 12 months blinded per subject . efficacy parameters

Eligibility criteria:
inclusion criteria: * subjects with allergic rhinoconjunctivitis with or without mild asthma fev1 ≥ 70%) for at least 2 years. their allergic symptoms should be related to grass pollen use of anti-allergy symptomatic medication in the last pollen season (or, in case of a low pollen season, in one of the two previous years) * a positive skin prick test (\>3 mm) for early flowering treesgrasses and specific serum ige-test(\>1 u/ml) for grass pollen (lolium perenne, phleum pratense and poa pratensis). exclusion criteria: * a positive spt for perennial allergens of house dust mite * allergy to any of the excipients * symptoms related to concomitant sensitisation to perennial allergens of pets * chronic asthma or emphysema, particularly with a fev1 \< 70 % of predicted value or use of inhalation corticosteroids outside grass and tree pollen season for more than two episodes and/or longer than fourteen days * use of symptomatic medication for more than three episodes and/or longer than three days outside the tree- or grass pollen season * serious immuno-pathological diseases or malignancies (including auto-immune diseases, tuberculosis, hiv) * inflammation and infection of the target organ * severe atopic dermatitis requiring systemic immuno-suppressive medication * allergen specific immuno-therapy treatment within the last 5 years for a period longer than three months * history of life threatening anaphylactic events, including anaphylactic food allergy, insect venom anaphylaxis, exercise or drug induced anaphylaxis * a positive pregnancy test, lactation or inadequate contraceptive measures alcohol- or drug abuse * lack of co-operation or severe psychological disorders

Keywords: sublingual immunotherapy rhinoconjunctivitis
serum pharmacokinetic disposition and urinary excretion of albendazole

Conditions: Soil Transmitted Helminthiasis; Neglected Tropical Diseases

Summary: mass drug administration (mda) of albendazole (abz) to school-age and pre-school-age children is the currently recommended strategy for controlling soil-transmitted helminthiasis (sth) in endemic areas. recent mathematical modelling suggests that community-wide mda will be required in order to interrupt transmission of sth. deworm3 aims to determine the feasibility of eliminating sth through expanded and intensified mda strategies. in order to ensure rigorous trial results, it is crucial that the definition of such mda coverage is informed by unbiased, empirical data. the centro de investigación veterinaria de tandil (civetan) and instituto de investigaciones en enfermedades tropicales universidad nacional de salta collaborate on scientific research related to pharmacokinetic studies of abz. this proposal describes the request for funding from deworm3 to conduct a study of the serum pharmacokinetic characteristics and urinary excretion of abz and its metabolites in non-infected human volunteers to better understand the use of urinary analysis of abz as a measure of mda adherence in the context of deworm3.

objective 1.to characterize the plasma disposition kinetics of abz and its main metabolites (abz sulphoxide and abz sulphone) in non-infected human volunteers. objective 2. to characterize the pattern of albendazole (abz) and its main metabolites (abz sulphoxide and abz sulphone) urinary excretion in non-infected human volunteers. objective 3. to determine the optimal and the longest period time after treatment where either abz and/or its metabolites can be measured in urine as an indirect assessment of an individual's adherence to treatment.

Eligibility criteria:
inclusion criteria: 1. weight between 45 and 75 kg. 2. physical exam without significant abnormal findings. exclusion criteria: 1. intake of abz or other benzimidazole drugs within the last 30 days. 2. malabsorption or other gi syndromes that could compromise the tolerability or absorption of abz. 3. history of hypersensitivity or intolerance to abz or its inactive ingredients. 4. acute clinical conditions. 5. pregnancy or breast feeding.
advancing nutritional science for children with functional dyspepsia

Conditions: Dyspepsia

Summary: this study evaluates four different meals and how they induce gastrointestinal symptoms in children with functional dyspepsia. all subjects will receive each meal and rate their gastrointestinal symptoms during each meal.

food can often exacerbate gastrointestinal symptoms in adults and children with functional dyspepsia. however, it is unclear which foods exacerbate symptoms more than others. children with post-prandial distress functional dyspepsia will receive four different meals with variables being: semi-solid vs. solid and high fat vs high carbohydrate. at the time of ingestion and for up to 3 hours after each meal, subjects will rate their gastrointestinal symptoms. comparisons of symptom onset and severity will be made for each meal. enrolled subjects will have undergone previous gastrointestinal evaluations: gastric emptying study and/or upper endoscopy. in addition, subjects will complete psychosocial measures: behavioral assessment for children-3, childhood somatization inventory. the first goal is to compare the severity of gastrointestinal symptoms with different composition and consistency meals. the second goal is to correlate the severity of postprandial gastrointestinal symptoms to psychosocial distress, gastric neuromotor function (emptying and accommodation), and duodenal inflammation.

Eligibility criteria:
inclusion criteria: * rome iv functional dyspepsia with post-prandial distress * previously completed normal upper endoscopy with duodenal biopsies and/or previously completed a gastric emptying scintigraphy study exclusion criteria: * previous abdominal surgery * current or previous formal psychiatric diagnosis (e.g. anxiety disorder) requiring therapy or psychotropics * serious chronic medical condition requiring regular medical care * allergy to meal components to be ingested during the study * on specialized diet required for a medical condition * pregnancy * inability to eat by mouth
rituximab in treating patients with non-hodgkin's lymphoma or hodgkin's disease

Conditions: Lymphoma

Summary: rationale: monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them. purpose: phase ii trial to study the effectiveness of rituximab in treating patients who have non-hodgkin's lymphoma or hodgkin's disease.

objectives: i. determine the response rate (complete or partial) to rituximab in previously untreated patients with stage iii or iv cd20+ b-cell follicular small cleaved cell non-hodgkin's lymphoma. ii. determine the response rate (complete or partial) to rituximab in patients with relapsed cd20+ hodgkin's disease. iii. determine the time to progression and time to chemotherapy in these patients after treatment with rituximab. outline: patients are stratified according to disease (follicular small cleaved cell non-hodgkin's lymphoma vs relapsed hodgkin's disease). patients receive rituximab iv over 4-6 hours on day 1 weekly for 4 weeks. patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter. projected accrual: a total of 21-32 patients will be accrued for each arm of this study within 7-10.5 months.

Eligibility criteria:
disease characteristics: histologically proven stage iiia or stage iva b-cell follicular small cleaved cell non-hodgkin's lymphoma tumor cells express cd20 no prior chemotherapy or radiotherapy stable disease that would otherwise be observed or histologically proven relapsed hodgkin's disease of any stage tumor cells express cd20 bidimensionally measurable disease masses (e.g., enlarged lymph nodes) must be at least 1.5 cm x 1.5 cm by ct, mri, or x-ray splenic enlargement considered measurable if spleen palpable at least 3 cm below the left costal margin no cns lymphoma patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: no more than 5,000 circulating tumor cells hepatic: not specified renal: not specified other: not pregnant or nursing fertile patients must use effective contraception during and for at least 12 months following study hiv negative no other active malignancies prior concurrent therapy: see disease characteristics

Keywords: recurrent adult hodgkin lymphoma stage iii grade 1 follicular lymphoma stage iv grade 1 follicular lymphoma
spectroscopy in ovarian cancer

Conditions: Ovarian Cancer; Ovarian Neoplasms; Ovary Cyst; Ovary Disease

Summary: ovarian cancer is the eighth most common cause of cancer death in the world. advanced stage at diagnosis is associated with lower survival rates, thus early detection appears to have an important role. raman spectroscopy is a non-invasive technique that uses the interaction of light to identify the composition of the sample tested. the aim of the project is to explore the use of spectroscopic techniques in the detection of ovarian cancer. there are two different assessments within the project: 1. identify ovarian cancer in blood - raman spectroscopic analysis will be performed on blood plasma taken from patients with suspected ovarian cancer. 2. detect active cancer within post chemotherapy fibrotic tissue - ex vivo raman spectroscopic analysis of peritoneal, omental or ovarian tissues collected from patients undergoing surgical treatment for ovarian cancer. the results of the spectroscopy will be correlated to clinical outcome and histological diagnosis respectively.


Eligibility criteria:
inclusion criteria: * female * symptoms suggestive of ovarian cancer * patients undergoing treatment of ovarian cancer exclusion criteria: * less than 18 years of age * unable to consent to the study due to communication difficulties * unable to consent to the study due to lack of capacity